drugset / Trial / NCT00915850
Trial of Docetaxel, Cisplatin, Fluorouracil (5-FU) for Unresectable Advanced Esophageal Squamous Cell Carcinoma (ESCC)
NaSingle-groupOpen-labelTreatment
Summary
This phase I/II study is being conducted to determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and efficacy of a combination chemotherapy using docetaxel, cisplatin and 5-fluorouracil (DCF) in unresectable advanced esophageal cancer. The usefulness of the this regimen is evaluated by RECIST, time to progression and median survival time.
Timeline
- Start
- 2007-08
- Primary completion
- 2010-08
- Completion
- 2015-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 12 mg/m2 | — |
| Subject | Docetaxel | Small molecule | 25 mg/m2 | — |
| Subject | Docetaxel | Small molecule | 30 mg/m2 | — |
| Subject | Docetaxel | Small molecule | 35 mg/m2 | — |
| Subject | Docetaxel | Small molecule | 40 mg/m2 | — |
| Subject | fluorouracil | Small molecule | 600 mg/m2 | — |